Table 4.
Univariate and multivariate Cox's regression analysis for OS
| Parameters | Univariate HR (95%CI) | P value | Multivariate HR# (95%CI) | P value |
|---|---|---|---|---|
| Treatment (cTACE vs. DEB-TAEC) | 1.763 (1.131, 2.749) | 0.012 | 1.654 (1.048, 2.608) | 0.031 |
| Age | 0.986 (0.966, 1.007) | 0.203 | - | - |
| Gender (Female vs. male) | 1.031 (0.665, 1.599) | 0.891 | - | - |
| HBV (no vs. yes) | 1.185 (0.540, 2.604) | 0.672 | - | - |
| ECOG PS score (1 vs. 0) | 1.343 (0.859, 2.099) | 0.196 | 1.326 (0.846, 2.078) | 0.219 |
| Child-Pugh stage (B vs. A) | 0.929 (0.521, 1.658) | 0.804 | - | - |
| Tumor number (multiple vs. single) | 1.997 (0.711, 2.993) | 0.025 | 1.852 (0.690, 2.895) | 0.037 |
| Tumor size | 1.820 (0.979, 2.563) | 0.042 | 1.734(0.832, 2.498) | 0.045 |
| Lymph node metastases (no vs. yes) | 0.829 (0.524, 1.312) | 0.424 | - | - |
| Ascites (no vs. yes) | 0.704 (0.322, 1.539) | 0.379 | - | - |
| ALT | 1.000 (0.996, 1.005) | 0.825 | - | - |
| Neutrophile | 1.015 (0.907, 1.137) | 0.792 | - | - |
| Lymphocyte | 1.311 (0.887, 1.937) | 0.175 | 1.213 (0.808, 1.820) | 0.352 |
| PLT | 1.001 (0.998, 1.003) | 0.697 | - | - |
| CA125 | 1.000 (0.999, 1.001) | 0.645 | - | - |
| CA199 | 1.000 (1.000, 1.000) | 0.991 | - | - |
| TACE session (≥2 vs. 1) | 1.150 (0.748, 1.766) | 0.524 | - | - |
| Previous treatments (no vs. yes) | 1.809 (0.751, 2.946) | 0.034 | 1.794 (0.742, 2.894) | 0.042 |
| PTCD/MRCP (no vs. yes) | 1.218 (0.756, 1.961) | 0.417 | - | - |
#variables with P value ≤0.2 in the univariate analysis were further included in the multivariate Cox proportional hazards regression model analysis. OS, overall survival; HR, hazard ratio; CI, confidence interval; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; HBV, hepatitis B virus; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALT, alanine aminotransferase; PLT, blood platelet; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; PTCD, percutaneous transhepatic cholangial drainage; MRCP, magnetic resonance cholangiopancreatography.